Capital Analysts LLC Purchases 521 Shares of Koninklijke Philips (NYSE:PHG)

Capital Analysts LLC boosted its position in shares of Koninklijke Philips (NYSE:PHG) by 6.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 8,820 shares of the technology company’s stock after purchasing an additional 521 shares during the period. Capital Analysts LLC’s holdings in Koninklijke Philips were worth $206,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Beverly Hills Private Wealth LLC bought a new position in Koninklijke Philips during the 4th quarter valued at about $230,000. NewEdge Wealth LLC increased its position in Koninklijke Philips by 3.2% in the 4th quarter. NewEdge Wealth LLC now owns 46,795 shares of the technology company’s stock valued at $1,092,000 after acquiring an additional 1,436 shares in the last quarter. Cerity Partners LLC increased its position in Koninklijke Philips by 7.7% in the 4th quarter. Cerity Partners LLC now owns 44,413 shares of the technology company’s stock valued at $1,036,000 after acquiring an additional 3,181 shares in the last quarter. Sequoia Financial Advisors LLC acquired a new stake in Koninklijke Philips in the 4th quarter valued at about $473,000. Finally, Inlet Private Wealth LLC increased its position in Koninklijke Philips by 9.0% in the 4th quarter. Inlet Private Wealth LLC now owns 226,160 shares of the technology company’s stock valued at $5,276,000 after acquiring an additional 18,580 shares in the last quarter. 13.67% of the stock is owned by institutional investors.

Koninklijke Philips Trading Down 0.8 %

Shares of NYSE:PHG opened at $19.98 on Friday. Koninklijke Philips has a one year low of $17.75 and a one year high of $24.27. The company has a 50 day moving average of $20.39 and a 200-day moving average of $20.85. The company has a current ratio of 1.20, a quick ratio of 0.78 and a debt-to-equity ratio of 0.58.

Koninklijke Philips (NYSE:PHG) last issued its quarterly earnings results on Monday, January 29th. The technology company reported $0.44 EPS for the quarter, topping the consensus estimate of $0.41 by $0.03. Koninklijke Philips had a negative net margin of 2.53% and a positive return on equity of 14.17%. The company had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.47 billion. On average, sell-side analysts anticipate that Koninklijke Philips will post 1.53 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on PHG shares. BNP Paribas cut shares of Koninklijke Philips from an “outperform” rating to an “underperform” rating in a research report on Wednesday, February 7th. StockNews.com upgraded shares of Koninklijke Philips from a “buy” rating to a “strong-buy” rating in a research report on Thursday, February 8th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $19.00.

About Koninklijke Philips

Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. The company operates through Diagnosis & Treatment Businesses, Connected Care Businesses, and Personal Health Businesses segments. It also provides diagnostic imaging solutions, includes magnetic resonance imaging, X-ray systems, and computed tomography (CT) systems and software comprising detector-based spectral CT solutions, as well as molecular and hybrid imaging solutions for nuclear medicine; echography solutions focused on diagnosis, treatment planning and guidance for cardiology, general imaging, obstetrics/gynecology, and point-of-care applications; integrated interventional systems, and interventional diagnostic and therapeutic devices to treat coronary artery and peripheral vascular disease.